Skip to main content Accessibility help
Hostname: page-component-684899dbb8-ndjvl Total loading time: 0.413 Render date: 2022-05-24T15:35:25.745Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

21 - Management of cancer of the bladder

Published online by Cambridge University Press:  05 November 2015

Samantha Cox
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Jacob Tanguay
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access


Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Advanced Bladder Cancer Meta-analysis Collaboration. (2003). Neoadjuvant chemotherapy in invasive bladder cancer: a systemic review and meta-analysis. Lancet, 361, 1927–1934.
Babjuk, M., Burger, M., Zigeuner, R., et al. (2013). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol., 64, 639–653.CrossRefGoogle ScholarPubMed
Bellmunt, J., von der Maase, H., Mead, G. M., et al. (2012). Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol., 30, 1107–1113.CrossRefGoogle ScholarPubMed
Bellmunt, J., Fougeray, R., Rosenberg, J. E., et al. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol., 24, 1466–1472.CrossRefGoogle ScholarPubMed
Burger, M., Catto, J.W., Dalbagni, G., et al. (2013). Epidemiology and risk factors or urothelial bladder cancer. Eur. Urol., 63, 234–241.CrossRefGoogle ScholarPubMed
De Santis, M., Bellmunt, J., Mead, G., et al. (2009). Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-based chemotherapy: phase II – results of EORTC study 30986.J. Clin. Oncol., 27, 5634–5639.CrossRefGoogle ScholarPubMed
Duchesne, G. M., Bolger, J. J., Griffiths, G. O., et al. (2000). A randomized trial of hypo-fractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of Medical Research Council trial BA09. Int. J. Radiat. Oncol. Biol. Phys., 47, 379–388.CrossRefGoogle Scholar
Efstathiou, J. A., Bae, K., Shipley, W. U., et al. (2009). Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. J. Clin. Oncol., 27, 4055–4061.CrossRefGoogle ScholarPubMed
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., et al. (2012). Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur. Urol., 61, 705–711.CrossRefGoogle ScholarPubMed
Gakis, G., Efstathiou, J., Lerner, S. P., et al. (2013). ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur. Urol., 63, 45–57.CrossRefGoogle ScholarPubMed
Harland, S. J., Kynaston, H., Grigor, K., et al. (2007). A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J. Urol., 178, 807–813.CrossRefGoogle ScholarPubMed
James, N. D., Hussain, S. A., Hall, E., et al. (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med., 366, 1477–1488.CrossRefGoogle ScholarPubMed
Jones, G., Cleves, A., Wilt, T. J., et al. (2012). Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD009294.CrossRefGoogle ScholarPubMed
Leow, J. J., Martin-Doyle, W., Rajagopal, P. S., et al. (2014). Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol., 66, 43–54.CrossRefGoogle ScholarPubMed
Millán-Rodriguez, F., Chéchile-Toniolo, G., Salvador-Bayarri, J., et al. (2000). Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol., 164, 680–684.CrossRefGoogle ScholarPubMed
Mowatt, G., N'Dow, J., Vale, L., et al. (2011). Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int. J. Technol. Assess. Health Care, 27, 3–10.CrossRefGoogle ScholarPubMed
Shelley, M., Cleves, A., Wilt, T. J., et al. (2011). Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev, 13(4). Art No.: CD008976.CrossRefGoogle Scholar
Shelley, M. D., Court, J. B., Kynaston, H., et al. (2003). Intravesical bacillus Calmette–Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev., (3), CD003231.Google ScholarPubMed
Smith, Z.L., Christodouleas, J. P., Keefe, S. M., et al. (2013). Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int., 112, 13–25.CrossRefGoogle Scholar
Snow-Lisy, D. C., Campbell, S. C., Gill, I. S., et al. (2014). Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes. Eur. Urol., 65, 193–200.CrossRefGoogle ScholarPubMed
Sylvester, R. J., Oosterlinck, W. and van der Meijden, A. P. (2004). A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol., 171 (6 Pt. 1), 2186–2190.Google ScholarPubMed
UICC. (2009). TNM Classification of Malignant Tumours, 7th edn, ed. Sobin, L.H., Gospodarowicz, M.K., Wittekind, Ch.. Chichester: Wiley-Blackwell, pp. 262–265.
von der Maase, H., Sengelov, L., Roberts, J. T., et al. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol., 23, 4602–4608.CrossRefGoogle ScholarPubMed
Wiesner, C., Pfitzenmaier, J., Faldum, A., et al. (2005). Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int., 95, 301–305.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats